Ocular Hypertension
📧 Sign up to get email alerts when something new happens for Ocular Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2026-04-09FDA Approved: COSOPT PF — Supplemental Application (Thea Pharma Inc.)
The FDA approved a supplemental application for COSOPT PF (dorzolamide hydrochloride and timolol maleate) by Thea Pharma Inc., marking an ad…
-
EMA approval · 2026-03-24EMA Authorised: Roclanda (Latanoprost;netarsudil mesilate) — Santen Oy
The European Medicines Agency has authorised Roclanda, a fixed-dose combination of latanoprost and netarsudil mesilate, for use in open-angl…
-
FDA approval · 2026-03-18FDA Approved: APRACLONIDINE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for apraclonidine from Sandoz Inc.
-
FDA approval · 2026-03-18FDA Approved: IOPIDINE 1% — Supplemental Application (Harrow Eye, LLC)
FDA approved a supplemental application for IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) from Harrow Eye, LLC, indicating a…
-
FDA approval · 2026-03-17FDA Approved: COMBIGAN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for COMBIGAN (brimonidine tartrate and timolol maleate) submitted by Allergan, Inc.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-03-11FDA Approved: BRIMONIDINE TARTRATE — Original Application (Gland Pharma Limited)
FDA approved the original application for brimonidine tartrate ophthalmic solution from Gland Pharma Limited. The approval adds a generic op…
-
FDA approval · 2026-02-25FDA Approved: TAFLUPROST OPHTHALMIC — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for tafluprost ophthalmic from Prasco Laboratories, enabling the marketing of a generic tafluprost o…
-
EMA approval · 2026-02-09EMA Authorised: Azopt (brinzolamide) — Novartis Europharm Limited
EMA authorised Azopt, brinzolamide 1% suspension, for open-angle glaucoma and ocular hypertension in the European Union. Novartis Europharm …
-
EMA approval · 2026-02-06EMA Authorised: Azarga (brinzolamide;timolol maleate) — Novartis Europharm Limited
EMA authorised Azarga, a fixed-dose combination of brinzolamide and timolol, for open-angle glaucoma and ocular hypertension; applicant: Nov…
-
EMA approval · 2026-02-05EMA Authorised: DuoTrav (travoprost;timolol) — Novartis Europharm Limited
The EMA authorised DuoTrav, a fixed-dose combination eye drop of travoprost and timolol by Novartis Europharm Limited, for open-angle glauco…
-
FDA approval · 2026-01-28FDA Approved: YUVEZZI — Original Application (Visus Therapeutics, Inc.)
The FDA approved YUVEZZI, a fixed-dose combination ophthalmic preparation of carbachol and brimonidine tartrate, under an original NDA from …
-
FDA approval · 2026-01-27FDA Approved: IDOSE TR — Supplemental Application (Glaukos Corporation)
FDA approved a supplemental application for IDOSE TR, a travoprost intracameral product from Glaukos Corporation.
-
EMA approval · 2026-01-23EMA Authorised: Travatan (travoprost) — Novartis Europharm Limited
EU marketing authorisation granted for Travatan eye drops (travoprost) by Novartis Europharm Limited for glaucoma (open-angle) and ocular hy…
-
EMA approval · 2026-01-23EMA Authorised: Simbrinza (brinzolamide;brimonidine tartrate) — Novartis Europharm Limited
The EMA authorised Simbrinza, a fixed-dose combination of brinzolamide and brimonidine tartrate, for the treatment of ocular hypertension an…
-
EMA approval · 2026-01-15EMA Authorised: Rhokiinsa (netarsudil) — Santen Oy
The EMA authorised Rhokiinsa (netarsudil) by Santen Oy for open-angle glaucoma and ocular hypertension.
-
FDA approval · 2025-12-17FDA Approved: LATANOPROST OPHTHALMIC SOLUTION — Original Application (Lifestar Pharma LLC)
FDA approved an original application for latanoprost ophthalmic solution from Lifestar Pharma LLC, providing a generic version of latanopros…
-
FDA approval · 2025-12-17FDA Approved: TRAVOPROST OPHTHALMIC SOLUTION — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Travoprost Ophthalmic Solution under an Original ANDA filed by Alembic Pharmaceuticals, indicated to reduce intraocular pressur…
-
FDA approval · 2025-11-21FDA Approved: BRIMONIDINE TARTRATE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for BRIMONIDINE TARTRATE submitted by Sandoz Inc.
-
FDA approval · 2025-10-09FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) submitted by Novartis Pharmaceuticals Corporation, resulting in chan…
-
FDA approval · 2025-10-01FDA Approved: DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for dorzolamide hydrochloride ophthalmic solution from Micro Labs Limited.
-
FDA approval · 2025-09-22FDA Approved: BIMATOPROST — Original Application (Amneal Pharmaceuticals NY LLC)
FDA approved the original application for bimatoprost from Amneal Pharmaceuticals NY LLC, enabling a generic version of the ophthalmic thera…
-
FDA approval · 2025-09-18FDA Approved: ALPHAGAN P — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for ALPHAGAN P (brimonidine tartrate) from Allergan, Inc., regarding labeling changes. The product i…
-
FDA approval · 2025-09-18FDA Approved: ALPHAGAN P — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Alphagan P (brimonidine tartrate) submitted by Allergan, Inc.
-
FDA approval · 2025-09-09FDA Approved: ZOLYMBUS — Original Application (Thea Pharma Inc.)
FDA approved ZOLYMBUS (bimatoprost) from Thea Pharma Inc. under NDA217307 as an ocular hypotensive agent to lower intraocular pressure in ad…
-
FDA approval · 2025-05-27FDA Approved: DORZOLAMIDE AND TIMOLOL — Supplemental Application (Leading Pharma, LLC)
FDA approval of a supplemental application for the dorzolamide and timolol combination ophthalmic solution from Leading Pharma, LLC.